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The virus-associated VAI RNA of adenovirus is a small highly structured RNA that is required for the efficient translation
of cellular and viral mRNAs at late times after infection. VAI RNA antagonizes the activation of the interferon-inducible
RNA-dependent protein kinase, PKR, an important regulator of translation. The RNA-specific adenosine deaminase, ADAR, is
an interferon-inducible RNA-editing enzyme that catalyzes the site-selective C-6 deamination of adenosine to inosine. ADAR
possesses three copies of the highly conserved RNA-binding motif (dsRBM) that are similar to the two copies found in PKR,
the enzyme in which the prototype dsRBM motif was discovered. We have examined the effect of VAI RNA on ADAR function.
VAI RNA impairs the activity of ADAR deaminase. This inhibition can be observed in extracts prepared from interferon-treated
human cells and from monkey COS cells in which wild-type recombinant ADAR was expressed. Analysis of wild-type and
mutant forms of VA RNA suggests that the central domain is important in the antagonism of ADAR activity. These results
suggest that VAI RNA may modulate viral and cellular gene expression by modulating RNA editing as well as mRNA
translation. © 1998 Academic Press
INTRODUCTION
RNA-specific adenosine deaminase (ADAR),2 also
known as dsRAD and DRADA, is an interferon-inducible
RNA-editing enzyme (Patterson and Samuel, 1995).
ADAR catalyzes the C-6 deamination of adenosine to
yield inosine in viral RNAs and cellular pre-mRNAs
(Bass, 1997). For example, ADAR catalyzes the site-se-
lective editing of hepatitis delta virus RNA (Polson et al.,
1996) and the cellular pre-mRNAs encoding the gluta-
mate-gated ion channel GluR receptor (Sommer et al.,
1991; Lomeli et al., 1994) and the serotonin 5-HT2c recep-
tor (Burns et al., 1997). In addition to selective RNA
editing of structured single-stranded RNA substrates,
ADAR can also deaminate adenosine-containing syn-
thetic double-stranded RNA substrates (Liu and Samuel,
1996; Nishikura et al., 1991; Polson and Bass, 1994). The
dsRNA deaminase activity is presumed to be responsi-
ble for the biased hypermutations observed during the
replication of negative-stranded RNA viral genomes dur-
ing lytic and persistent infections, as exemplified by
measles virus (Cattaneo et al., 1988; Wong et al., 1989;
Cattaneo, 1994). However, hypermutation deamination is
not limited to viruses with RNA genomes; extensive
adenosine modifications have also been identified in the
early transcripts of the DNA virus polyoma virus (Kumar
and Carmichael, 1997). The A to I deaminations observed
in both cellular pre-mRNA transcripts and viral RNAs are
dependent upon double-stranded structures within the
substrate RNA. The dsRNA binding properties of the
purified ADAR proteins (Hough and Bass, 1994; Kim et
al., 1994a; Nishikura et al., 1991; O’Connell and Keller,
1994) are similar to those of the IFN-inducible RNA-
dependent protein kinase PKR (Samuel, 1979, 1993).
cDNA and genomic clones of the human ADAR deami-
nase have been isolated and characterized. The human
ADAR protein is a 1226-amino-acid protein as deduced
from the cDNA sequence (Kim et al., 1994b; O’Connell et
al., 1995; Patterson and Samuel, 1995) that is encoded by
an IFN-inducible ;6.7-kb transcript (Patterson et al.,
1995) that undergoes alternative splicing (Liu et al., 1997).
The human ADAR gene maps to chromosome 1q21.1–
21.2 (Weier et al., 1995). ADAR deaminase possesses
three copies of the highly conserved dsRNA binding
motif dsRBM (Patterson and Samuel, 1995; Liu and Sam-
uel, 1996) that was first identified in PKR kinase (McCor-
mack et al., 1992; Green and Mathews, 1992) and Droso-
philia Staufen protein (St. Johnston et al., 1992). The
codon phasing of exons 3, 5, and 7 encoding the three
dsRBM motifs in human ADAR (Liu et al., 1997) are
exactly conserved and identical to the two dsRBM motif-
containing exons of about 40 amino acids each present
in both human (Kuhen et al., 1996) and mouse (Tanaka
1 To whom reprint requests should be addressed. Fax: (805) 893-4724.
2 The abbreviations used: Ad, adenovirus; ADAR, dsRNA-specific
adenosine deaminase; dsRNA, double-stranded RNA; dsRBM, dsRNA
binding motif previously designated R-motif; IFN, interferon; kb, kilo-
base; nt, nucleotide; PKR, RNA-dependent protein kinase; VA, virus-
associated.
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and Samuel, 1994) PKR. Three splice-site variants of the
ADAR protein have been identified. They all retain the
dsRBM motif subdomains functionally intact, but pos-
sess deletions of 19 and 26 amino acids between the
dsRBMII and dsRBMIII subdomains and the dsRBMIII and
catalytic subdomains, respectively, which result in func-
tionally distinct enzymes (Liu et al., 1997).
Adenovirus virus-associated (VA) RNAs are small reg-
ulatory RNAs transcribed by RNA polymerase III
(Mathews and Shenk, 1991). They are highly structured
RNAs, about 160 nt in size. Three structural features of
the VAI RNA from Ad2 and Ad5 include two long imper-
fectly base-paired stem regions, the terminal stem and
the apical stem-loop, which are linked by a central do-
main (Ma and Mathews, 1996a,b). VAI RNA accumulates
to high concentrations in the cytoplasm at late times after
adenovirus infection (Soderlund et al., 1976), is required
for efficient protein synthesis (Schneider et al., 1984), and
antagonizes the IFN-induced antiviral response in ade-
novirus-infected cells (Kitajewski et al., 1986). One of the
principle targets of VA RNA is the RNA-dependent pro-
tein kinase PKR (Mathews and Shenk, 1991; Samuel,
1991). PKR is an IFN-inducible cellular protein kinase that
plays a central role in the antiviral action of IFN and the
control of translation in virus-infected cells (Samuel,
1993; Clemens, 1996). VAI RNA binds to the dsRNA bind-
ing motifs of PKR (McCormack et al., 1992; McCormack
and Samuel, 1995) and blocks the dsRNA-dependent
activation of PKR by autophosphorylation (Kitajewski et
al., 1986; O’Malley et al., 1986). Activated PKR catalyzes
the phosphorylation of the a subunit of protein synthesis
initiation factor eIF-2 at serine 51 (Samuel, 1979; Pathak
et al., 1988), which leads to an inhibition of translation
(Clemens, 1996). In the case of adenovirus, VAI RNA
competes with the dsRNA activator of PKR believed to be
synthesized by symmetrical transcription of the viral ge-
nome (Maran and Mathews, 1988). Because ADAR and
PKR are both IFN-inducible proteins (Patterson and Sam-
uel, 1995; Patterson et al., 1995; Meurs et al., 1990;
Thomis et al., 1992), because ADAR and PKR are both
RNA-binding proteins that possess the same highly con-
served dsRBM (Patterson and Samuel, 1995; McCor-
mack et al., 1992; Liu et al., 1997), and because it is
well-established that the adenovirus VAI RNA antago-
nizes the activation and function of the PKR kinase
(Mathews and Shenk, 1991; Samuel, 1993), we consid-
ered the possibility that VAI RNA may also antagonize the
ADAR RNA editing enzyme.
We report here the effect of adenovirus VAI RNA on the
function of the ADAR deaminase. VAI RNA inhibited
ADAR and was not a detectable substrate of ADAR.
ADAR activity present in extracts prepared from either
IFN-treated cells or from untreated cells transfected with
a cDNA clone encoding wild-type ADAR was inhibited by
VAI RNA. Analysis of VAI RNA mutants indicated that the
central domain region was important for the inhibition of
ADAR as well as the antagonism of PKR.
RESULTS
Adenovirus VAI RNA inhibits RNA-specific adenosine
deaminase activity
The interferon inducible RNA-specific ADAR deami-
nase contains three copies of the dsRNA-binding motif
originally identified in the IFN-inducible RNA-dependent
protein kinase PKR (Patterson and Samuel, 1995; Liu et
al., 1997). The RNA-dependent activation of the PKR ki-
nase, an important regulator of translation, is selectively
antagonized by adenovirus VAI RNA (Samuel, 1993;
Mathews and Shenk, 1991). To explore the possible re-
lationship between adenovirus VAI RNA and ADAR ac-
tivity, cytoplasmic extracts prepared from IFN-treated U
cells were examined for their ability to catalyze the
deamination of 32P-labeled dsRNA substrate in the pres-
ence of VAI RNA. As shown by the analysis of the ADAR
deaminase activity by TLC (Fig. 1A), wild-type VAI RNA
added to the standard ADAR reaction mixture reduced
the amount of inosine formed. The inhibition of deami-
nase activity was dependent upon the concentration of
added VA RNA; maximal inhibition was observed be-
tween 10 and 20 mg VAI RNA/ml (Fig. 1B). Bulk transfer
RNA did not significantly affect deaminase activity (Fig.
1B). 32P-labeled VA RNA was also examined as a sub-
strate in place of [32P]dsRNA in the standard ADAR
reaction mixture. As measured by the formation of ino-
sine detected by TLC and autoradiography, wild-type VAI
RNA was not a substrate for ADAR (data not shown). The
effect of HIV TAR RNA on ADAR activity was also exam-
ined. TAR(1-82) RNA did not antagonize ADAR activity
measured with dsRNA substrate under conditions com-
parable to those in which VA RNA did antagonize ADAR
activity, and TAR RNA itself was not a detectable sub-
strate of the deaminase (data not shown).
Inhibition of recombinant RNA-specific adenosine
deaminase by VAI RNA is independent
of the N-terminus of ADAR
The ADAR cDNA expressed in transfected COS cells,
either as the full-length protein (M1 ADAR) or as a trun-
cated protein lacking the N-terminal 295 residues (M296
ADAR), possesses dsRNA adenosine deaminase activity
(Patterson and Samuel, 1995; Liu et al., 1997). The deami-
nase activity associated with recombinant human ADAR
expressed in monkey COS cells was inhibited by VAI
RNA (Fig. 2). Both the M1 ADAR and the truncated M296
ADAR enzymes were inhibited by the addition of VAI RNA
to the reaction mixture (Fig. 2). The results shown in Fig.
2 were obtained with the ADAR-b splice-site variant (Liu
et al., 1997). We also found that VAI RNA inhibited the
deaminase activity of the recombinant ADAR-a and
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ADAR-c variants, both as the M1 and M296 forms of the
protein (data not shown). Characterization of mutant
ADAR proteins possessing single amino acid substitu-
tions in dsRBMI, dsRBMII, and dsRBMIII has established
that dsRBMIII is the most important for deaminase activ-
ity and that dsRBMII is least important (Liu and Samuel,
1996; Liu et al., 1997). Consistent with these earlier ob-
servations, the dsRBMIII mutant of M1 ADAR did not
display significant enzymatic activity in either the ab-
sence or the presence of added VAI RNA (Fig. 2). By
contrast, the dsRBMII mutant of M296 ADAR, which dis-
played significant deaminase activity in the absence of
VAI RNA, was inhibited by the addition of VAI RNA to the
reaction mixture (Fig. 2). The low residual activity of the
dsRBMI mutant was further reduced by addition of VAI
RNA (Fig. 2).
FIG. 1. Effect of VAI RNA on ADAR deaminase activity present in extracts of interferon-treated human cells. The effect of adenovirus wild-type VAI
RNA on double-stranded RNA-dependent adenosine deaminase (ADAR) activity was measured with cytoplasmic extracts prepared from interferon-
treated human U cells. The indicated concentration of unlabeled Ad VAI RNA or transfer RNA was added to the reaction mixture before addition of
the 32P-labeled dsRNA substrate. (A) Autoradiogram showing ADAR deaminase activity. Inosine formation was analyzed by thin-layer chromatography;
the positions of AMP, IMP, and the origin are indicated. (B) Quantitation of ADAR deaminase activity observed in the standard reaction mixture
containing U cell extract and either wild-type VAI RNA (open circles) or bulk tRNA (filled circles) as indicated.
FIG. 2. Effect of VAI RNA on the activity of recombinant wild-type and mutant human ADAR proteins expressed in transfected COS cells. Wild-type
and mutant forms of the human ADAR cDNA were expressed in transfected monkey COS cells. Cytoplasmic extracts were prepared and analyzed
for ADAR protein expression and enzyme activity with 32P-labeled dsRNA substrate. (A) Autoradiogram showing ADAR deaminase activity in the
absence (2) and the presence (1) of 12.5 mg/ml of VAI RNA. Inosine formation was analyzed by thin-layer chromatography; the positions of AMP, IMP,
and the origin are indicated. (B) Quantitation of ADAR deaminase activity. Deaminase activity was calculated based on the percentage of A-to-I
conversion catalyzed per equivalent amount of expressed ADAR protein determined by Western immunoblot analysis (Liu et al., 1997). Two forms of
wild-type (WT) ADAR were expressed: M1, wild-type full-length protein; M296, N-terminal truncated protein beginning at methionine 296. ADAR
proteins possessing a substitution mutation in one of the three RNA-binding domains included RI (K554E), RII (K665E), and RIII (K776E), which were
expressed as either the full-length or the M296 protein version (Liu et al., 1997).
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Ability of VAI RNA mutants to inhibit the RNA-specific
adenosine deaminase
Three previously described VAI RNA substitution mu-
tants (Rahman et al., 1995) and four newly generated VAI
RNA deletion mutants were examined for their ability to
inhibit the deaminase activity of recombinant ADAR (Fig.
3). The precise positions of the mutations are shown in
the Table 1 schematic. The three single nucleotide sub-
stitution mutants, pm89, pm91, and pm132, are within the
central domain region of the secondary structure model
predicted for VAI RNA (Furtado et al., 1989; Ma and
Mathews, 1996). Two of the deletion mutants, dlB1 and
dlB7, are within the apical stem-loop region, and the
other two deletion mutants, dlC and dlD, are within the
terminal stem region. Adenosine deamination of [32P]-
dsRNA substrate, catalyzed by recombinant ADAR in a
standard reaction mixture supplemented with either
wild-type or the indicated mutant VAI RNA, was quanti-
fied by measurement of the amount of inosine formed in
the presence compared to the absence of added VA
RNA. All RNAs were examined at a concentration of 12.5
mg/ml, the concentration of wild-type VAI RNA that
caused an 80% inhibition of ADAR activity (Fig. 1). Figure
3 shows the relative inhibition obtained with each mutant
RNA. Based on their capacity to inhibit ADAR, VAI RNA
mutants can be placed into three groups (Table 1). The
first group is represented by the dlC mutant RNA which
lacks the 39-terminal nine nucleotides. This mutant was a
potent inhibitor of ADAR (96% inhibition), as was the
wild-type VAI RNA. The second group consists of mu-
tants pm89, pm91, dlB1, and dlD. Although these mutants
possess changes positioned in different regions of the
linear VAI RNA sequence, they all displayed an interme-
diate inhibitory effect on ADAR, ranging from 47 to 59%.
FIG. 3. Ability of mutant VAI RNAs to inhibit the deaminase activity of
recombinant wild-type ADAR. Mutant or wild-type VAI genes were
transcribed in vitro and the purified RNAs were examined for their
ability to inhibit the deamination of 32P-labeled dsRNA substrate cata-
lyzed by recombinant ADAR. Deaminase activity was determined in the
absence and presence of 12.5 mg/ml of each of the indicated effector
VAI RNAs. Inosine formation was quantitated as described under Ma-
terials and Methods. The relative inhibition percentage was calculated
from the relationship 100 minus X, where X is equal to the percentage
of deaminase activity observed in the presence of added VAI RNA
compared to that in the absence of added RNA under standard reaction
conditions.
TABLE 1
Antagonism of ADAR Deaminase and PKR Kinase by VAI RNA
0 20 40 60 80 100 120 140 160
VAI RNA ADAR inhibitor a PKR inhibitor b
WT 1 1
89 U 3 G
pm89 1 1
91 A 3 U
pm91 1 2
132 A 3 G
pm132 2 2
70 77
dlB1 1 2
71 90
dlB7 2 2
151
dlC 1 1
131 152
dlD 1 1
Note. Effect of VAI RNA mutants on the activity of the ADAR deaminae and PKR kinase. (Left) Schematic diagram showing the
nucleotide (nt) positions of the mutations in the VAI RNAs examined. The substitutions (pm) and deletions (dl) are indicated with nt
number. (Right) Summary of the functional activity of VAI RNAs. The PKR results for pm89, pm91, and pm132 are from Ranman et al.
(1996).
a Ability of VAI RNA to inhibit ADAR deaminase activity.
b Ability of VAI RNA to inhibit the autophosphorylation of protein kinase PKR.
Ç Ç Ç Ç Ç Ç Ç Ç Ç
Ç
Ç
Ç
Ç Ç
Ç Ç Ç
Ç Ç
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The third group of mutant RNAs includes pm132 and
dlB7. Their ability to inhibit ADAR was severely dimin-
ished, causing only a 22% reduction or less in deaminase
activity (Fig. 3).
Comparison of the effects of VAI RNA on
RNA-specific adenosine deaminase ADAR
and RNA-dependent protein kinase PKR
Previous studies established that the central domain
of VAI RNA is of critical importance in the antagonism of
activation of the RNA-dependent protein kinase (PKR) by
Ad VAI RNA (Furtado et al., 1989; Clarke and Mathews,
1995; Green et al., 1995; Rahman et al., 1995). Three
site-directed substitution mutations in the central domain
region of VAI RNA have differential effects on PKR acti-
vation: point mutant pm89 inhibits PKR autophosphory-
lation, whereas pm91 and pm132 do not antagonize PKR
activation (Rahman et al., 1995). Our results, summarized
by Table 1, reveal that these three VAI RNA point mutants
affect ADAR function differently from how they affect PKR
activation. For example, pm89 can inhibit PKR activation
as efficiently as WT VAI RNA (Rahman et al., 1995), but
the ability of pm89 to inhibit ADAR is reduced relative to
that of WT VAI RNA. Mutant pm91 cannot block PKR, but
it retains its capacity to inhibit ADAR. Only pm132 loses
its ability to block both PKR and ADAR, possibly because
the VAI RNA secondary structure involving the central
domain may be substantially altered by the A to G nu-
cleotide substitution (Rahman et al., 1995).
We generated four deletion mutants of VAI RNA. Two of
them are within the apical duplex region, and the other
two are in the lower duplex region. Mutant dlB1 pos-
sesses a six-nucleotide deletion within the apical stem
near to the upper loop; this mutant retains the capacity to
efficiently inhibit ADAR activity, but it is a poor antagonist
of PKR. Mutant dlB7 possesses a much larger deletion
(18 nt) within the apical stem, extending from the apical
loop to the central domain; this mutation most likely
affects the secondary structure of the apical stem as well
as the central domain structure. Mutant dlB7 does not
inhibit either ADAR or PKR. Mutant dlC is a 39-truncation
mutant in which the terminal nine nucleotides involved in
the base-paired terminal stem of VAI RNA are deleted.
The dlC mutant blocks PKR as efficiently as WT VAI RNA
and ADAR even somewhat more efficiently than WT VA
RNA. Mutant dlD possesses a large (20-nt) internal de-
letion within the terminal stem region of VAI RNA, ex-
tending from the central domain to the bottom of the
stem. This mutant VAI RNA inhibited both ADAR and PKR.
DISCUSSION
The double-stranded RNA adenosine deaminase,
ADAR, is an interferon-inducible RNA-editing enzyme
(Patterson and Samuel, 1995; Patterson et al., 1995)
which catalyzes the C-6 deamination of adenosine to
yield inosine within RNA (Bass, 1997). The results
reported herein establish that adenovirus VAI RNA
impairs the deaminase activity of ADAR. This finding
has important implications related to the antiviral ac-
tions of interferon and antisense-mediated inhibition
of gene expression.
Adenovirus VAI RNA is a ;160-nt regulatory RNA
found in abundant amounts in the cytoplasm of infected
cells at late times after infection (Mathews and Shenk,
1991). Our results establish that VAI RNA can inhibit
ADAR deaminase activity. Both natural ADAR present in
extracts from IFN-treated human U cells (Fig. 1) and
recombinant ADAR expressed in transfected monkey
COS cells (Fig. 2) were inhibited by VAI RNA. An ;1000-
fold molar excess of wild-type VA RNA over the synthetic
dsRNA substrate was required to observe maximal inhi-
bition of deaminase activity. Very little is known about
naturally occurring RNAs that may be targets for adeno-
sine deamination by ADAR and thus in vivo candidates
for impairment of the deamination by adenovirus VA RNA
at late times in infection. Conceivably the relative differ-
ence in concentration or binding affinity between target
substrates and VA RNA in vivo are less or, alternatively,
additional interacting proteins may play a role in vivo in
modulating the relative affinity of the ADAR deaminase
for substrate RNAs versus effector RNAs.
The principle function previously elucidated for VAI
RNA relates to its ability to antagonize the activation of
PKR, the RNA-dependent inhibitor of translation
(Mathews and Shenk, 1991; Samuel, 1993). PKR plays a
key role in the antiviral and antiproliferative actions of
interferon (Samuel, 1991; Lengyel, 1993). PKR, like ADAR,
is an IFN-inducible enzyme (Samuel, 1993; Clemens,
1996). Indeed, VAI RNA is the best characterized RNA
antagonist of the PKR kinase. It is well-established that
adenoviruses are relatively resistant to the antiviral ac-
tions of interferon (Stewart, 1979). This resistance is due,
at least in part, to the antagonism of PKR function by VAI
RNA. PKR possesses two copies of the dsRBM motif that
possesses RNA-binding activity (McCormack et al., 1992,
1995; Green and Mathews, 1992). VAI RNA binds to PKR
via dsRBM motifs and prevents the subsequent auto-
phosphorylation and activation of PKR kinase activity by
dsRNA activators (Kitajewski et al., 1986; O’Malley et al.,
1986; Mathews and Shenk, 1991; Samuel, 1993).
How could VAI RNA further antagonize the antiviral
action of interferon? ADAR possesses three copies of
the highly conserved dsRBM motif which are responsible
for binding of the substrate RNAs for deamination (Kim
et al., 1994b; Patterson and Samuel, 1995; O’Connell et
al., 1995; Liu et al., 1997). In addition to dsRNA sub-
strates, ADAR also catalyzes the deamination of selec-
tive adenosine residues in structured viral RNAs and
cellular pre-mRNAs (Bass, 1997). VA RNA could impair
ADAR activity by either competing with the binding of the
substrate RNA or alternatively by affecting the conforma-
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tion of ADAR in such a manner that abrogates deamina-
tion of bound substrate RNA. Interestingly, a ribonucle-
ase specific for inosine-containing RNA has been iden-
tified in HeLa cells (Scadden and Smith, 1997). The
IFN-inducible ADAR deaminase (Patterson et al., 1995)
may conceivably work in concert with the RNase-I spe-
cific for inosine-containing RNAs (Scadden and Smith,
1997), analogous to the manner in which the IFN-induc-
ible 29,59-oligoadenylate synthetase functions to produce
the 29,59-oligoadenylate activator of the constitutively ex-
pressed ribonuclease L (Samuel, 1991; Zhou et al., 1993).
The antagonism of the IFN-induced ADAR deaminase by
VAI RNA would be expected to reduce the formation of
inosine-containing RNA transcripts and thus impair the
formation of potential substrates for RNase-I.
From a comparison of our results for the VAI-mediated
antagonism of ADAR with those observed for PKR, two
important points emerge. First, our results obtained with
mutants of VAI RNA suggest that the central domain of VAI
RNA is essential for its ability to inhibit ADAR and that the
apical duplex stem may be more important than the termi-
nal stem. The central domain and an adjacent region in the
apical stem are likewise important for the binding of VA
RNA to PKR and for the functional impairment of PKR
activity (Furtado et al., 1989; Clarke et al., 1994; Green et al.,
1995; Rahman et al., 1995). Second, the interactions of VAI
with ADAR and PKR, while similar, are not equivalent. For
example, pm91 and dlB1 do not significantly inhibit PKR, but
both of these mutants inhibit ADAR reasonably well (Table
1). The basis for this difference is unknown, but may be
related to the fact that ADAR possesses three copies of the
dsRBM motif, whereas PKR has only two copies. Although
the sequences of the dsRBM motifs are highly conserved,
the individual motifs do display functional differences in
ADAR (Lai et al., 1995; Liu and Samuel, 1996) and PKR
(McCormack et al., 1995; Green et al., 1995). Because the
central domain of VAI RNA does not possess a double-
stranded stem as found in perfectly paired dsRNA, but yet
we observe that the central domain of VAI RNA is important
for the inhibition of ADAR deaminase activity, it is not un-
expected that VAI RNA is not a substrate of ADAR.
We did not observe an inhibitory effect of TAR RNA on
ADAR activity, even though TAR RNA is bound by ADAR
(Patterson and Samuel, 1995) and is reported to be
deaminated in a Tat-dependent manner (Sharmeen et al.,
1991). The lack of inhibition of ADAR by TAR may relate to
the fact that ADAR possesses three copies of the dsRBM
(Kim et al., 1994b; Patterson and Samuel, 1995). Mu-
tagenesis studies have revealed that dsRBM3 is abso-
lutely essential for deamination of a synthetic dsRNA
substrate, whereas dsRBM1 and dsRBM2 are not (Liu
and Samuel, 1996; Liu et al., 1997). For the PKR kinase
which possesses two copies of the dsRBM, binding of
RNA does not necessarily correlate with function. For
example, in vitro selection experiments have identified
multiple RNA sequences that bind to the dsRBM of PKR
with comparable Kd values; some selected RNAs func-
tion as agonists or antagonists, whereas others do not
significantly affect PKR activity (Bevilacqua et al., 1998).
The replicative form of single-stranded RNA virus ge-
nomes (Cattaneo, 1994) or symmetrical transcripts of
double-stranded DNA virus genomes such as adenovi-
rus (Maran and Mathews, 1988) may serve as potential
sources of double-stranded RNA in virus-infected cells
and thus targets for the biased hypermutation via deami-
nation by ADAR. Antisense-induced regulation of tran-
script levels via extensive adenosine deamination has
been reported for polyoma virus (Kumar and Carmichael,
1997). Site-selective editing of adenovirus mRNA tran-
scripts would provide another potential target for ADAR,
similar to the highly selective editing established for the
GluR and 5HT2c cellular pre-mRNAs (Lomeli et al., 1994;
Burns et al., 1997). Although not yet established for ad-
enovirus-infected cells, it is conceivable that either post-
transcriptional selective editing of adenovirus mRNA or
an antisense-mediated inhibition of gene expression, or
both, occurs during adenovirus multiplication. VAI RNA,
which accumulates to high concentrations at late times
after infection, would have the potential to modulate such
editing by ADAR.
Although extensive evidence from several laboratories
has unequivocally established that VAI RNA functions to
enhance protein synthesis, by a mechanism that involves
the antagonism of the translation inhibitor PKR (Mathews
and Shenk, 1991), this does not preclude other additional
roles for VAI RNA. For example, it has been reported that
VAI RNA has a role in controlling mRNA stability (Strijker
et al., 1989). VAI RNA also has been found to increase
cytoplasmic RNA abundance in an RNA length-depen-
dent manner (Svensson and Akusjarvi, 1990). It is now of
utmost importance to establish the functional signifi-
cance of the antagonism of the ADAR deaminase by VAI
RNA, in the context of both the regulation of adenovirus
gene expression and the antiviral actions of interferon.
EXPERIMENTAL PROCEDURES
Cell culture, interferon treatment, and transfection
Human amnion U cells, either untreated or treated with
IFN-a (1000 units/ml), were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 5% (v/v)
fetal bovine serum (FBS, Hyclone) as previously described
(Patterson and Samuel, 1995). Monkey kidney COS cells
maintained in DMEM supplemented with 10% (v/v) FBS
were used to express recombinant ADAR proteins, either
wild-type ADAR (Patterson and Samuel, 1995) or mutant
ADAR with substitutions in copy I, II, or III of the dsRBM
(previously designated RI, RII, or RIII mutants) (Liu and Sam-
uel, 1996). Transfections with the ADAR cDNAs using the
pcDNA I/neo expression vector were by the DEAE–dextran/
chloroquine phosphate method (Luthman and Magnusson,
1983) using 5 mg of DNA/ml when the cultures in 60-mm
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dishes were about 70% confluent. Cells were harvested 48
to 60 h after transfection and extracts were prepared as
previously described (Patterson and Samuel, 1995; Liu et
al., 1997). ADAR protein expression was monitored by West-
ern immunoblot analysis as described previously, using
antiserum generated against recombinant ADAR protein
expressed in Escherichia coli (Patterson and Samuel, 1995).
Adenovirus VAI RNA plasmid constructions and in
vitro transcription
The pT7VA plasmid with the wild-type adenovirus type 2
VAI RNA gene cloned downstream of the T7 promoter
(Mellits et al., 1990) was generously provided by Dr. Mi-
chael Mathews (Cold Spring Harbor Laboratory, New York).
The pT7TAR plasmid was as previously described (McCor-
mack et al., 1992). Single-base substitution mutants pm89,
pm91, and pm132 of the Ad5 VAI RNA gene (Rahman et al.,
1995) were kindly provided by Dr. Bayar Thimmapaya
(Northwestern University Medical School). Deletion mu-
tants dlB1, dlB7, dlC, and dlD were generated from plasmid
pT7VA. All DNA manipulations were carried out by standard
recombinant DNA technology (Sambrook et al., 1989). To
generate dlB1 and dlB7, pT7VA was linearized with BamHI
and then treated with S1 nuclease. Recessed ends were
blunted with T4 DNA polymerase prior to plasmid closure
using T4 DNA ligase. dlC was generated by digestion of
pT7VA with Eco47III prior to in vitro transcription. dlD was
generated by digestion with AatII and EcoR47III to delete
the 20-nt AatII–EcoR47III fragment and treated with T4 DNA
polymerase to remove the 39 overhangs, and then the
gel-purified plasmid fragment was reclosed using T4 DNA
ligase. All VAI RNA mutations were confirmed by direct
sequence determination by the dideoxy chain-termination
method (Sanger et al., 1977). For in vitro transcription, plas-
mid DNA constructions (5 mg) were linearized as follows:
wild-type VA plasmid construction, with DraI or PstI; dlB1,
dlB7, and dlD, with DraI; dlC, with Eco47III; and, pm89,
pm91, and pm132 with EcoRI. Transcription was with T7
RNA polymerase (Promega) according to the manufactur-
er’s instructions. In vitro transcripts were subjected to or-
ganic solvent extraction, ethanol precipitation, and gel elec-
trophoresis, and they displayed the anticipated size char-
acteristics (McCormack et al., 1992; Kitajewski et al., 1986).
Double-stranded RNA-specific adenosine deaminase
assay
The assay conditions for measurement of ADAR activ-
ity using 32P-labeled dsRNA substrate were as described
previously (Patterson and Samuel, 1995; Liu and Samuel,
1996). The standard reaction mixture (40 ml) contained
about 10 fmol of synthetic 32P-labeled dsRNA substrate
and varying amounts of cytoplasmic extract protein as
indicated in 50 mM Tris–HCl buffer, 100 mM KCl, 5 mM
EDTA, 10% (v/v) glycerol, 1 mM DTT, and 0.5 mM phenyl-
methylsulfonyl fluoride. Where noted, VAI RNA was
added to the reaction mixture and preincubated on ice
with the ADAR-containing extract prior to addition of the
32P-labeled dsRNA substrate. The complete reaction
mixture was incubated at 30°C for 2 h and then extracted
with phenol–chloroform and chloroform. RNA was recov-
ered by ethanol precipitation in the presence of 0.5 mg of
poly(rI) (Sigma) carrier RNA, washed with 70% ethanol,
dried, and suspended in 10 ml of nuclease digestion
buffer (30 mM KOAc, pH 5.3, 10 mM ZnSO4) containing
1.5 mg of P1 nuclease (Pharmacia Biotech, Inc.). Incuba-
tion was at 50°C for 2 h. IMP and AMP were resolved
from each other by thin-layer chromatography (TLC) on
cellulose NM300 glass plates (Macherey and Nagel) in a
solvent consisting of saturated (NH4)2SO4, 100 mM NaAc
(pH 6.0), and isopropanol (79:19:2). Radioactivity corre-
sponding to IMP and AMP was quantified using a Beck-
man LS1801 liquid scintillation system. Quantitated val-
ues from three independent experiments are shown with
standard error determinations.
Double-stranded RNA-dependent protein kinase PKR
assay
Procedures for measurement of the VAI RNA-mediated
antagonism in vitro of the [g-32P]ATP-mediated autophos-
phorylation of PKR were essentially as described before
in detail (Samuel et al., 1986; Kitajewski et al., 1986). The
standard reaction mixture (25 ml) included HPLC-purified
human PKR protein, eIF-2 (0.25 mg), and VAI RNA (0.5 mg)
as indicated, which were preincubated prior to addition
of synthetic poly(rI):poly(rC) dsRNA and [g-32P]ATP. The
complete reaction mixture was then incubated at 30°C
for 15 min. 32P-labeled protein products were fraction-
ated by SDS–polyacrylamide gel electrophoresis and
quantified as previously described (Samuel et al., 1986).
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